Your browser doesn't support javascript.
loading
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.
Vinci, Mara; Burford, Anna; Molinari, Valeria; Kessler, Ketty; Popov, Sergey; Clarke, Matthew; Taylor, Kathryn R; Pemberton, Helen N; Lord, Christopher J; Gutteridge, Alice; Forshew, Tim; Carvalho, Diana; Marshall, Lynley V; Qin, Elizabeth Y; Ingram, Wendy J; Moore, Andrew S; Ng, Ho-Keung; Trabelsi, Saoussen; H'mida-Ben Brahim, Dorra; Entz-Werle, Natacha; Zacharoulis, Stergios; Vaidya, Sucheta; Mandeville, Henry C; Bridges, Leslie R; Martin, Andrew J; Al-Sarraj, Safa; Chandler, Christopher; Sunol, Mariona; Mora, Jaume; de Torres, Carmen; Cruz, Ofelia; Carcaboso, Angel M; Monje, Michelle; Mackay, Alan; Jones, Chris.
Afiliação
  • Vinci M; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Burford A; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Molinari V; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Kessler K; Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
  • Popov S; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Clarke M; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Taylor KR; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Pemberton HN; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Lord CJ; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Gutteridge A; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Forshew T; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Carvalho D; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Marshall LV; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Qin EY; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Ingram WJ; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Moore AS; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Ng HK; Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK.
  • Trabelsi S; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • H'mida-Ben Brahim D; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Entz-Werle N; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Zacharoulis S; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Vaidya S; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Mandeville HC; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Bridges LR; Stanford University School of Medicine, Stanford, CA, USA.
  • Martin AJ; CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
  • Al-Sarraj S; CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
  • Chandler C; UCL Cancer Institute, University College London, London, UK.
  • Sunol M; UCL Cancer Institute, University College London, London, UK.
  • Mora J; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • de Torres C; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Cruz O; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Carcaboso AM; Paediatric Oncology Drug Development Team, Children and Young People's Unit, Royal Marsden Hospital, Sutton, UK.
  • Monje M; Stanford University School of Medicine, Stanford, CA, USA.
  • Mackay A; UQ Child Health Research Centre, The University of Queensland, Brisbane, Queensland, Australia.
  • Jones C; Oncology Services Group, Children's Health Queensland Hospital and Health Service, Brisbane, Queensland, Australia.
Nat Med ; 24(8): 1204-1215, 2018 08.
Article em En | MEDLINE | ID: mdl-29967352
ABSTRACT
The failure to develop effective therapies for pediatric glioblastoma (pGBM) and diffuse intrinsic pontine glioma (DIPG) is in part due to their intrinsic heterogeneity. We aimed to quantitatively assess the extent to which this was present in these tumors through subclonal genomic analyses and to determine whether distinct tumor subpopulations may interact to promote tumorigenesis by generating subclonal patient-derived models in vitro and in vivo. Analysis of 142 sequenced tumors revealed multiple tumor subclones, spatially and temporally coexisting in a stable manner as observed by multiple sampling strategies. We isolated genotypically and phenotypically distinct subpopulations that we propose cooperate to enhance tumorigenicity and resistance to therapy. Inactivating mutations in the H4K20 histone methyltransferase KMT5B (SUV420H1), present in <1% of cells, abrogate DNA repair and confer increased invasion and migration on neighboring cells, in vitro and in vivo, through chemokine signaling and modulation of integrins. These data indicate that even rare tumor subpopulations may exert profound effects on tumorigenesis as a whole and may represent a new avenue for therapeutic development. Unraveling the mechanisms of subclonal diversity and communication in pGBM and DIPG will be an important step toward overcoming barriers to effective treatments.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glioblastoma / Neoplasias do Tronco Encefálico Limite: Animals / Child / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glioblastoma / Neoplasias do Tronco Encefálico Limite: Animals / Child / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article